Conclusion
TED, proptosis, low clinical disease activity
DISEASE, PROPTOSIS
The results from this randomized controlled study add to the increasing body of literature from real-world clinical practice on teprotumumab's efficacy in treating TED. These data demonstrate that teprotumumab significantly reduced proptosis from baseline with a higher rate of proptosis response compared with placebo in patients with longstanding TED and low clinical disease activity. These data taken collectively with previous study results demonstrate teprotumumab's efficacy in TED regardless of disease duration or activity, as indicated in the US FDA label (